Immunomodulatory and biologic therapies for severe refractory asthma  by Polosa, Riccardo & Morjaria, Jaymin
Respiratory Medicine (2008) 102, 1499e1510ava i lab le at www.sc ienced i rec t . com
journa l homepage : www.e lsev ier . com/ loca te / rmedEVIDENCE-BASED REVIEW
Immunomodulatory and biologic therapies
for severe refractory asthma*Riccardo Polosa a,*, Jaymin Morjaria ba Ospedale Santa Marta, U.O.C di Medicina Interna e Medicina d’Urgenza, Via Gesualdo Clementi 36, 95124 Catania, Italy
b Department of IIR, University of Southampton, Southampton, UK
Accepted 30 July 2008KEYWORDS
Severe asthma;
Corticosteroids;
Immunological
modifiers;
Steroid-sparing;
Anti-TNFalpha drugs;
Omalizumab* The following Cochrane reviews ha
sparing agent for asthma in adults, Is
2004; Evans DJ, Cullinan P, Geddes D
Evans DJ, Cullinan P, Geddes DM. Cycl
Geddes DM. Gold as an oral corticost
topurine for inducing remission of Cro
2, 2006.
* Corresponding author. Tel.: þ39 09
E-mail address: polosa@unict.it (R
0954-6111/$ - see front matter ª 200
doi:10.1016/j.rmed.2008.09.006Summary
Despite undoubted efficacy of the combination of inhaled corticosteroids and b2-agonists for
most asthmatic patients with moderate-to-severe disease, there remains w10% of the asth-
matic population with serious unremitting symptoms, resulting in considerable impact on
quality of life, disproportionate use of health care resources, and adverse effects from regular
systemic steroid use. In an ideal world, optimal treatment of severe refractory asthma should
achieve the best possible asthma control and quality of life with the least dose of systemic
corticosteroids. The choice and formulation of therapeutic agent are dictated by the severity
of disease and may include immunological modifiers and biologic therapies. Unfortunately,
current asthma guidelines offer little contribution to the management of the challenging
patient with severe refractory asthma and none of them have addressed therapeutic alterna-
tives to oral corticosteroids. This article reviews the current evidence for immunomodulating
and biologic approaches in severe refractory asthma.
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Most patients with asthma have mild-to-moderate disease
easily controlled by regular use of inhaled corticosteroids
(ICS) combined with short-acting inhaled b2-agonists for
relief of symptoms. However, in a small subset of patients,
asthma continues to be poorly controlled in terms of
ongoing symptoms, frequent exacerbations, persistent and
variable airway obstruction and frequent requirement for
b2-agonists despite aggressive treatment.
1 The accurate
prevalence of such cases is unknown, but may fluctuate
around 5e8% of the total asthma population, depending on
the definition of severe refractory asthma.2,3 A working
definition of severe chronic asthma has been recently
developed on the basis of the level of intensity of
corticosteroid treatment required to minimize symptoms
(Table 1).4
Severe refractory asthma (SRA) is 2e3 times more
common in women, is characterised by a component of
irreversible airflow obstruction and peripheral airways
disease, neutrophilic inflammation, ongoing mediator
release, and a reduced association with atopy. These obser-
vations imply that SRA might be a ‘different disease’ with
features that are distinct from mild-to-moderate asthma.5
Patients with SRA have the greatest impairment of their
lifestyles and account for a disproportionate use of health
care resources through hospital admissions, unscheduled
doctors’ visits, and use of emergency services.6e8
In a patient with intractable respiratory symptoms
(wheeze, breathlessness, chest tightness, and cough)
despite frequent requirement for b2-agonists and adminis-
tration of substantial dose of inhaled and/or oral cortico-
steroids, physicians should consider the possibility of SRA.Table 1 American Thoracic Society workshop consensus
for definition of severe/refractory asthmaa
Major characteristics
- Treatment with continuous or near continuous
(50% of year) oral corticosteroids
- Need for treatment with high-dose inhaled
corticosteroids
Minor characteristics
- Need for additional daily treatment with a controller
medication (e.g. long-acting b-agonist, theophylline,
or leukotriene antagonist)
- Asthma symptoms needing short-acting b-agonist
use on a daily or near-daily basis
- Persistent airway obstruction (FEV1< 80% predicted,
diurnal peak expiratory flow variability >20%)
- One or more urgent care visits for asthma per year
- Three or more oral steroid bursts per year
- Prompt deterioration with 25% reduction in
systemic corticosteroid dose
- Near-fatal asthma event in the past
a Definition requires that at least one major criterion and two
minor criteria are met, other disorders have been excluded,
exacerbating factors have been treated, and patient is gener-
ally compliant.Certain conditions need to be systematically excluded and
form part of the differential diagnosis of SRA.1
Current asthma guidelines offer little contribution to the
management of the challenging patient with SRA and none
of them have addressed therapeutic alternatives to high-
dose ICS combined with a long-acting inhaled b2-agonist
(LABA) and oral corticosteroids.9 Moreover, there remain
a significant number of patients with severe unremitting
disease that require regular systemic corticosteroids in
order to minimize symptoms and exhibit a deterioration as
soon as the dose of corticosteroids is tapered. Some
excellent review articles on this topic have been publish-
ed,1,10e12 but very little attention has been paid to
complementary therapeutic options.
In this review article, we appraise former and recent
findings of immunological modifiers and biologic therapies
used in patients with SRA in order to inform physicians
about their potential role in this challenging condition.
Methodology of the review
The overall methodology for this systematic review follows
the directives published by the Cochrane Collaboration
(see: www.cochrane.org/resources/handbook/Handbook4.
2.6Sep2006.pdf).
Full-text papers were identified on the basis of a litera-
ture search in the Cochrane Central Register of Controlled
Trials and MEDLINE (January 1966 to June 2007). The terms
for the electronic search were severe asthma/or/refractory
asthma/or/steroid-dependent asthma/AND/therapy/or/
azathioprine/or/cyclosporin/or/TNF/or/etanercept/or/infli
ximab/or/macrolides/or/gold/or/methotrexate/or/omaliz
umab. We limited our search to titles and abstracts of
human studies published in English. All randomised-
controlled trials (RCTs) and crossover-controlled trials
(CCTs) of immunological modifiers and biologic therapies
in steroid-dependent asthmatics were included. The main
outcome of interest was the decrease in oral steroid
dose. The search also identified a small number of clin-
ical trials of poor quality with hydroxychloroquine and
colchicine; their findings were inconclusive and they were
not included in this review.
This article examines the respective immunological
modifiers and biologic drugs by focusing on key studies to
critically appraise effects in terms of key efficacy outcomes
and safety. Some commentary is provided in order to help
physicians with their clinical decision-making.
Immunological modifiers for severe refractory
asthma (Table 2)
In order to minimize the need for long-term systemic
steroids, and to reduce their adverse effects, an explor-
atory trial with alternative anti-inflammatory and immu-
nologic modifiers such as thiopurines (azathioprine (AZT)),
macrolide anti-bacterials, cyclosporin A, gold and metho-
trexate (MTX), should be considered. If, however, the
addition of these drugs does not lead to a substantial
reduction in oral corticosteroid requirement within 24e36
weeks, they should be withdrawn. Careful monitoring of
patients’ symptoms and laboratory tests are mandatory to
Table 2 Immunological modifiers for severe refractory asthma
Drug Evidence for
efficacy
No. of
patients
Significant
reduction in
OCS dose
Improvements in other
parameters
Common side effects for
agent
Thiopurines
(AZT)
Hodges et al.17 (CS) 10 No Increase in airway
conductance. - GI upsets (diarrhoea,
nausea, vomiting)
- Flu-like symptoms
Hodges et al.17 (CS) 13 No e
Macrolides
(TAO)
Ball et al.23 (DBPC) 15 Yes Improvement in AHR.
- Steroid related side
effects (for TAO)
Kamada et al.24 (DBPC) 18 Yes Improvement in AHR,
asthma symptoms.
Nelson et al.25 (DBPC) 57 Yes Reduction in hospital
admissions, ER attendances
and OCS boosts.
Cyclosporin
A
Alexander et al.38 (CS) 30 Not
assessed
Improvements in PEF, FEV1.
Reduction in asthma
exacerbations.
- Hypertrichosis
- Hypertension
- Paraesthesias
- GI upsets (nausea,
diarrhoea)
- Flu-like symptoms
Lock et al.36 (DBPC) 36 Yes Improvements in morning
PEF.
Nizankowska et al.37 (DBPC) 32 No Reduction in symptoms
scores and reliever use.
Gold Klaustermeyer et al.49 (DBPC) 8 No e
- GI upsets (abdominal
pain, diarrhoea)
- Pruritic rash
Nierop et al.45 (DBPC) 28 Yes Improvements in symptom
scores, FEV1. Reductions
in OCS boosts.
Bernstein et al.46 (DBPC) 279 Yes e
MTX Mullarkey et al.52 (CS) 13 Yes e
- LFT abnormalities
- GI upsets (abdominal
pain, nausea, diarrhoea)
- Oral ulcers and stomatitis
Dyer et al.54 (CS) 10 Yes e
Shiner et al.53 (DBPC) 60 Yes Reduction in asthma
exacerbations.
Erzurum et al.55 (DBPC) 17 Noa e
Trigg et al.56 (CS) 12 No e
Taylor et al.57 (CS) 9 No e
Stewart et al.58 (DBPC) 21 Noa Improvements in
subjective and physician
symptom scores.
Coffey et al.59 (DBPC) 11 Yes e
Kanzow et al.60 (DBPC) 21 Noa e
Ogirala et al.61 (DBPC) 19 No Improvements in FEV1,
PEF, AHR.
Reduction in hospital
admissions and ER
attendances.
Hedman et al.62 (CS) 12 Yes Reduction in reliever use.
Comet et al.63 (DBPC) 46 Yes e
CS, crossover study; DBPC, double-blind placebo-controlled study; OCS, oral corticosteroids; AZT, azathioprine; TAO, troleandomycin;
AHR, airway hyper-responsiveness; ER, emergency room; CSA, cyclosporin A; PEF, peak expiratory flow; FEV1, forced expiratory volume
in 1 s; QoL, quality of life.
a Significant within group improvements in the respective agent group.
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these immunologic modifiers to evaluate their efficacy and
safety in chronic severe asthmatics. Of note is that a number
of trials discussed in this section are similar to those in
Cochrane reviews, due the limited number of RCTs and CCTs
that have been conducted in the respective agents.Thiopurines
Azathioprine (AZT) and its metabolite 6-mercaptopurine
(MCP) are known to induce lymphopenia and reduce T-cell
numbers.13 They have been used for more than 30 years as
steroid-sparing immunomodulatory agents. Rheumatoid
1502 R. Polosa, J. Morjariaarthritis (RA), organ transplant recipients, chronic active
hepatitis and inflammatory bowel disease are some of
conditions in which AZT has been used.14e16
The evidence
Two double-blind placebo-controlled randomised (DBPC)
trials, with crossover design, in patients with stable oral
corticosteroid (OCS)-dependent asthma meeting our inclu-
sion criteria, will be discussed here.17 Hodges et al.17
recruited adult asthmatics with poorly controlled severe
chronic asthma with a predicted FEV1 of 21e48% and an OCS
dose of 7e30 mg over a duration of 2e6 years. Ten subjects
were randomised by a neutral observer to receive AZT
(2 mg/kg) or placebo in addition to normal medication for 3
weeks. No significant reductions in OCS use, arterial oxygen
partial pressure, lung function (FEV1 and FVC) and asthma
symptoms (cough, wheeze and climbing stairs) were repor-
ted between the 2 groups. There was a small significant
difference in favour of AZT in airway conductance. The other
study by the same group17 was carried out in a similar fashion
in 13 OCS-dependent adult severe asthmatics. Allocation by
subjects to the groups (AZT (5 mg/kg) or placebo) was per-
formed by a neutral observer and the drugs were adminis-
tered over 4 weeks. Similar to the previous study there were
no significant reductions in OCS consumption, improvement
in PEF or asthma symptoms between the 2 groups.
Adverse events
In the latter trial, 3 subjects in the AZT group suffered an
asthma exacerbation during the first treatment period and
participants were subsequently withdrawn from the
study.17 Mild myelosuppression was reported with a small
but significant reduction in white cell count in the AZT
group.17 Occasional dyspepsia and herpes labialis were also
reported. No hospitalisations occurred during treatment in
either study.
Implications for practice and research
There are a number of problems with these two studies.
Firstly, it is unlikely that AZT administration for such a short
period of time (3e4 weeks) could have been playing
a significant role. Secondly, neither study formally assessed
the effect of AZT on OCS consumption. However, anecdotal
reports described 2 patients (1 from each trial) were able to
reduce their OCS consumption when they resumed treat-
ment with AZT, but this occurred outside the randomised
comparison period. Thirdly, the very low FEV1% predicted,
the lack of reversibility data and the significant sputum
production in patients of both studies appear to suggest that
some of them may have had COPD and been incorrectly
enrolled. Fourthly, the number of subjects in the studies was
small, notwithstanding the dropouts. Given these important
methodological problems, the role of AZT in OCS-dependent
asthma continues to be uncertain. To elucidate any signifi-
cant steroid-sparing role for thiopurines in SRA, larger high
quality randomised-controlled trials would be required.
Macrolide anti-bacterials
The initial experience with macrolides in treating chronic
asthma dates back almost 40 years and began primarilywith troleandomycin (TAO), a potent steroid-sparing agent
with specific inhibitory effects on methylprednisolone (MP)
clearance.18 Improvement in asthma symptoms did not
appear to be correlated with a direct anti-microbial
effect.19,20 Important benefits to patients with chronic
asthma have been also reported with the newer macro-
lides21,22 and they are consistent with the notion that these
drugs act as biological modifiers, attenuating respiratory
tract inflammation.
The evidence
There have been 3 randomised DBPC parallel-group trials
that have studied the effect of TAO in OCS-dependent
asthmatics.23e25 The dose of 250 mg daily of TAO was used
in all studies. Two of these were conducted in a small
number of children with OCS-dependent asthma and shared
similar protocols.23,24 Both studies reported substantial
reductions in OCS usage in the TAO group (by at least 50% in
the study by Ball et al.23), but significant reductions in the
Kamada et al. study were also observed in the placebo
group.24 An improvement in the airway hyper-responsive-
ness (AHR) to methacholine after TAO was also observed in
both studies. Specifically, for the TAO group of the study by
Kamada et al.24 a significant 50% reduction in asthma
symptoms was reported. The third study was a much larger
and longer trial in 75 steroid-dependent adult subjects
randomised to receive TAO or placebo for 1 year.25 For
some of the study subjects, a single blind phase was added
for an additional year. There was no formal tapering of
steroids prior to study entry. Steroid tapering was
attempted throughout the study if PEF measurements and
asthma symptoms remained stable or improved. In the 57
subjects who completed the double-blind phase of the
study, it was reported a significant reduction in mean daily
steroid dose both in the TAO (from 30.8 to 6.3 mg/day) and
in the placebo group (from 32.8 to 10.4 mg/day). Moreover,
no differences were observed between the 2 study groups
in terms of the number of hospitalisations and emergency
room attendances, asthma control, and AHR to
methacholine.
The effect of clarithromycin (500 mg twice daily for 6
weeks) has been investigated in a small randomised DBPC
pilot study of 21 asthmatic patients with daily OCS
requirements of 5 mg/day.26 In this study, an overall
improvement in lung function (FVC, but not FEV1) and
symptoms was reported together with a concomitant
reduction in prednisone usage. Interestingly, in 3 patients
who continued clarithromycin therapy for 1 year, 2 of the 3
patients discontinued prednisone and no serious adverse
effects, bacterial resistance or immunosuppression were
reported.27
In the recent study by Simpson et al.28 45 subjects with
SRA (44% received at least one course of oral prednisone in
the past year) were randomised to receive either clari-
thromycin (500 mg twice daily) or placebo for 8 weeks as
add-on therapy. Steroid dose reduction was not included as
a study endpoint. Treatment significantly reduced inflam-
matory outcomes (sputum IL-8, sputum neutrophils),
improved asthma-related quality of life (AQLQ) scores, and
reduced self-reported wheezing compared with placebo,
specifically in the subgroup of patients with non-eosinophilic
asthma.
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With reference to safety issues unrelated to steroid side
effects, there is an overall shortage of data. Interestingly
the important side effect of TAO, namely abnormalities of
liver function did not emerge as a major problem. In the
TAO group, Nelson et al.25 reported more cases of bone
loss, higher cholesterol levels and reduction in IgG levels.
Unlike TAO, no serious adverse events were reported in any
of the trials with clarithromycin.
Implications for practice and research
In a Cochrane systematic review of macrolides in chronic
severe asthma, a meta-analysis of 90 patients recruited
into the 3 TAO studies,23e25 demonstrated that there was
no treatment effect in terms of steroid dose reduction.29
Similarly, for measures of lung function, a meta-analysis of
the data from the studies by Kamada et al.24 and Nelson
et al.25 showed no benefit for the addition of TAO. It must
be noted that the studies carried out in the paediatric
populations not only included a very small number of
subjects, but their treatment duration was far too short to
appropriately assess TAO efficacy. In the study by Nelson
et al.25 there were a substantial number of dropouts, which
impairs interpretation of their findings. Also, in the trials by
Ball et al.23 and Nelson et al.25 there was no formal OCS
tapering protocol. Although preliminary data on the use of
clarithromycin in SRA appears to indicate some beneficial
effects, future large placebo-controlled studies in OCS-
dependent asthma are required to establish the true
potential of this drug as a biological modifier.
Cyclosporin A
Cyclosporin A (CSA) is a fungal metabolite that is commonly
known for its inhibitory effect on T-cell activation.30,31 The
use of CSA in asthma was implicated as T-cells have been
shown to play a significant role in asthma pathogenesis.32
CSA has been reported to antagonise the late-phase asth-
matic reaction (LAR),33 inhibit eosinophil-related cytokine
production following allergen challenge34 and attenuating
AHR.35
The evidence
Two prospective DBPC studies36,37 and one placebo-
controlled crossover study38 have examined the efficacy of
CSA (5 mg/kg/day) in OCS-dependent asthmatics. Alex-
ander et al.38 studied 33 asthmatic patients with a mean
OCS usage of 8.5 mg/day. After a 4-week run-in period,
they received CSA or placebo orally for 12 weeks. CSA
therapy showed significant improvements compared to
placebo in lung function (mean increase of 12% and 17.6% in
morning PEF and FEV1, respectively) and exacerbations
(48% reduction in the frequency of disease exacerbations)
but no differences in symptom scores or rescue medication
use. Although no specific OCS reduction was attempted, 11
weeks of run-out demonstrated that the mean morning PEF
was significantly higher compared to baseline in the CSA
group. In another DBPC parallel-group study by Lock et al.36
39 severe adult asthmatics on a mean prednisone dose of
12 mg/day were randomised to receive CSA (nZ 19) or
placebo (nZ 20) for 36 weeks. After a 4-week run-inperiod, patients randomised to receive CSA or placebo,
with OCS tapering attempted from week 12 of treatment by
a blinded physician if the patients’ asthma remained stable
or improved on a 2-weekly basis. A significant reduction in
the median daily OCS usage from baseline (62%; from 10 to
3.5 mg/day) for the CSA-treated group (nZ 16; 3 with-
drawals) compared to the placebo group (25%; from 10 to
7.5 mg/day) was reported. Besides the significant reduction
in OCS, there were marked improvements in morning PEF
for the CSA group. In a similarly designed study, Nizan-
kowska et al.37 studied 34 OCS-dependent adult asthmatics
on a mean prednisone dose of 16 mg/day were randomised
to receive CSA or placebo for 36 weeks. No run-in period
was included, but the lowest dose of steroid maintaining
stable state of asthma was predetermined at the beginning
of the trial. Significant reductions in OCS dose were
observed in both study groups (CSA group: from 15.9 to
9.8 mg/day; placebo group: from 16.5 to 12.2 mg/day), but
no significant difference between the groups. Also, it was
observed that there was a small but significant difference in
symptom scores and rescue medication use in favour of the
CSA-treated group, however no improvements between the
2 study groups in terms of lung function.
Of note, CSA in open-labelled studies and case reports in
OCS-dependent asthma have been shown to allow OCS dose
reduction and improvements in asthma control.39,40 In fact,
there are a small number of subjects who actually are
responders when treated over 9 months with CSA40 and that
withdrawal of CSA resulted in a rapid relapse of asthma
symptoms and increase in use of OCS to pre-CSA treatment
doses.41
Adverse events
CSA toxicity is well described in transplant literature, with
dose-dependent nephrotoxicity being themain concern.Mild
renal impairment, abnormal liver function tests, increase in
blood pressure, increase incidence of hypertrichosis and
paraesthesia have been reported.36e40 These side effects
usually reversed upon discontinuation of CSA therapy.
Implications for practice and research
The trials discussed vary in methodology and have certain
limitations that have impact on the interpretation of the
results. All 3 trials were small with approximately 30
patients in each and hence a Type 2 statistical error cannot
be excluded for the non-significant results. In the crossover
study by Alexander et al.38 admonition should be expressed
about the brief washout period between the treatment
arms. Meta-analyses were limited by differences in the way
data for steroid doses were expressed by the two steroid-
sparing trial designs.36,37 Despite these problems there were
statistically significant effects of CSA on steroid doses. For
the study by Nizankowska et al.37 this effect amounted to
a mean reduction of 6.1 mg in the CSA treated patients and
4.3 mg in the placebo treated patients. Likewise in the study
by Lock et al.36 there was an even smaller incremental
reduction in the daily steroid dose. These minor reductions
in OCS reduction may be of uncertain clinical importance.
From the safety viewpoint there are definite changes in
blood pressure and renal function, hence careful monitoring
is important when using CSA. Although further trials with
more subjects and longer duration are necessary to
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it should be taken into account that long-term use in other
chronic inflammatory conditions such as RA and ulcerative
colitis is burdened by a substantial failure rate.42,43
However, novel cyclosporin analogues with much improved
safety profiles, such as tacrolimus and pimecrolimus, which
are effective for atopic dermatitis that is refractory to
corticosteroid treatment, should be tested in SRA.
Gold
Gold is an immunological modifier that has been used in
inflammatory and autoimmune conditions including RA. Gold
sodium thiomalate (GST), gold thioglucose and auranofin are
examples of gold agents, of which the former 2 are admin-
istered parenterally and the latter orally. Not only is the
mechanism of action of gold poorly understood, but also the
action of oral and parenteral gold is thought to be different.44
The evidence
Three DBPC studies of OCS-dependent asthmatics, 2 with
oral gold45,46 and one with parenteral gold49 were identified.
Klaustermeyer et al.49 studied 10 asthmatic patients with
a mean OCS dose of 21.15 mg/day. They were randomised to
receive parenteral gold in the form of aurothioglucose 50 mg
(nZ 6) or matched placebo (nZ 4) by intramuscular injec-
tions weekly for 22 weeks. There were no OCS tapering
attempts made prior to enrolment. Two subjects from the
treatment group and 1 from the placebo group were with-
drawn due to heavy proteinuria (after weeks 4 and 15) and
gas transfer abnormalities. Although there were significant
improvements in the parenteral gold group compared to
placebo, it was reported that 5 out of 8 subjects on paren-
teral gold improved in terms of reducing OCS requirements
while maintaining or improving their lung function.
In the first study using oral gold, Nierop et al.45 recruited
32 severe asthmatics with a mean OCS dose of 7.9 mg/day.
Subjects were randomised to receive either auranofin 3 mg
twice daily or matched placebo for 26 weeks, however no
prior OCS tapering was attempted during or prior to the 1
week run-in period. The subjects were reviewed on a 2-
weekly basis with tapering initiation at 12 weeks if appro-
priate. One patient was withdrawn from placebo due to
non-compliance, and 3 (2 in the gold-treated group and 1 in
placebo) due to severe eczema resistant to topical treat-
ment. It was reported that the treated group achieved
a significantly greater reduction in steroid use (auranofin
group: from 9.3 to 5.3 mg/day; placebo group: from 11 to
10.7 mg/day). Correspondingly, there were significant
differences between the 2 groups, in favour of gold, for
improvements in symptom scores, FEV1, and courses of
added prednisone for exacerbations.
In the largest trial, the Auranofin Multicentre Drug
Trial,46 275 adult subjects with daily OCS requirements of
10 mg/day were randomised to receive either auranofin
3 mg twice daily or placebo for 6 months, where the
primary outcome was therapeutic success as defined as at
least 50% reduction in OCS from baseline. Efforts to taper
the OCS dose were attempted in the 3 months prior to
screening, with the majority of subjects being on
10e19 mg/day. Assessments were conducted on a 2-weekly
basis with steroid tapering commencing at 12 weeks ifappropriate. Although the results were limited by a signifi-
cant patient dropout rate in both study groups and no
intention-to-treat analyses performed, a significant overall
reduction in OCS use of 41% in the gold-treated group was
achieved compared to 27% in the placebo group. However,
no differences between groups for lung function, symptoms
or concomitant medication use were observed.
Of note, in an open-labelled study of auranofin in 18
steroid-dependent asthmatics for 24 weeks, the overall
steroid-sparing effect was associated with attenuation in
AHR.47 Interestingly, the study demonstrated a subgroup
response, whereby 13 subjects reduced OCS dose by 72%,
but 5 increased their OCS slightly.
Adverse events
Side effects from gold therapy are common but mild.
Proteinuria, severe exacerbations of eczema and mucocu-
taneous reactions to gold may compel withdrawal from gold
treatment.45e49 Other commoner and milder side effects
reported include gastrointestinal upset, urticaria and
stomatitis. Side effects are normally self-limiting with
discontinuation or reduction of therapy.
Implications for practice and research
Inadequacies of the discussed studies include discrepancies
in the ICS use, lack of tapering prior to randomisation,
besides the small numbers and short duration of 2 of the
studies.45,49 A meta-analysis of 376 subjects in the studies
above45,46,49 has demonstrated a small but significant
improvement in favour of gold as a steroid-sparing agent.44
Furthermore, given the various possible mechanisms of
action and established differences in pharmacological
profiles between auranofin and parenteral gold, compari-
sons of these 2 agents for steroid-sparing effects and effi-
cacy are difficult. It also important to acknowledge that the
results of the meta-analysis were driven by the large
sample size of the study by Bernstein et al.46 From the
studies discussed, oral gold appears to be a useful steroid-
sparing agent with acceptable toxicity. Further larger,
adequately powered, DBPC studies are needed to deter-
mine long-term efficacy and safety of gold on SRA.
Methotrexate
Methotrexate (MTX) is a folic acid inhibitor that antagonises
the enzyme dihydrofolate reductase, in doing so impeding
thymidine synthesis and consequently hampering DNA
synthesis and cell division. Whereas at higher doses
(>50 mg/week) it is useful as an anti-mitotic agent for
leukaemia,50 at lower doses (5e25 mg/week) MTX possesses
immunosuppressive and anti-inflammatory properties,51 of
which the exact mechanisms are poorly understood.
The evidence
MTX has been the most investigated immunological modifier
in asthma. The first trial to elucidate the steroid-sparing
effect of MTX was a DBPC crossover study conducted by
Mullarkey et al. in 1988.52 This was soon followed by a DBPC
parallel-group study published by Shiner et al.53 In the study
by Mullarkey et al.52 22 adult OCS-dependent asthmatics
with a mean initial prednisone dose of 24.8 mg/day were
recruited to receive oral MTX (15 mg/week) or placebo for 24
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attempts to taper steroid doses before the trial were given.
Participants were subjected to dose reduction by 5 mg every
5 days if their symptoms improved. In the 13 subjects who
completed the study it was reported that in the MTX group
there was a significant (36.5%) reduction in OCS use
compared to placebo. A similar DBPC crossover study in 12
adults with OCS-dependent asthma with a mean initial
prednisone dose of 13.1 mg/day was conducted with a 3-
week run-in OCS taper period, a 12-week randomised period
and 4-week washout, followed by a 12-week crossover. A
significant (30%) reduction in OCS use was observed with MTX
(15 mg/week). In the study by Shiner et al.53 69 OCS-
dependent asthmatics with a mean initial prednisone dose
7.5 mg/day for at least 1 year before the trial were rand-
omised to receive either MTX (15 mg/week) or placebo. Total
duration of the trial was 38 weeks. It had a 4-week run-in,
a 24-week treatment and 10-week run-out periods. OCS
tapering was attempted every 4 weeks of treatment, if
asthma remained stable or improved. In the 60 subjects who
completed the study (32 in theMTX armand 28 in the placebo
arm), it was reported that there was a significant 50%
reduction in OCS with MTX compared to placebo. The final
dose fell to 6.6 mg/day compared to a 14% fall in OCS dose in
the placebo group whose final dose was 12.9 mg/day. Of
note, the steroid-sparing effect of MTX was not evident until
after 12 weeks of treatment, and this effect did not persist
when MTX was stopped, with subjects reverting to baseline
OCS requirements in their run-out periods.
Since these initial observations, many other well-con-
ducted studies evaluated the use of MTX in SRA.55e63 Most of
the studies recruited subjects who were taking regular OCS
(>10 mg/day) and used oral MTX at doses of at least 15 mg/
week. The duration of treatment ranged from 12 to 24 weeks
with no long-term follow-up, with the exception of the study
by Comet et al.63 where MTX was given for 12 months. For 3
of these studies,59,62,63 a significant reduction in OCS dose
with MTX was reported, whereas in the remaining 6 studies
no significant change between MTX and placebo was
observed.55e58,60,61
An important placebo effect was noted in most studies
with significant reductions in OCS use, that could be
attributed to the increased multiple follow-ups and patient
education. Only a few trials had tapering of OCS in the run-
in to maximise treatment prior to enrolment.56,60,63
Treatment with MTX was noted only to have very minimal
and often no significant improvements in FEV1,
56,58
subjective assessment of breathing ability,52 reduction in
daily bronchodilator use and asthma symptoms.62
In two separate prospective open-labelled extension
studies64,65 of 31 and 21 subjects respectively, treated with
15 mg/week of MTX for up to 28 months, it has been
reported that there were statistically significant reductions
in baseline OCS dosage with over half being weaned off all
OCS. These long-term studies answered previous concerns
regarding the possibility of tachyphylaxis or unusual toxic-
ities unique to asthma when MTX is used to treat SRA.
Recently, the data from a well-designed, DBPC study of 46
steroid-dependent asthmatic patients treated with MTX
(10 mg/week) for 12 months has become available.63 In this
study, a substantial reduction (>50%) in OCS dose was
observed in the MTX group compared to the placebo group.At the end of the study, the OCS dose decreased from 17.3
to 7.8 mg/day in the MTX group, but only from 12.8 to
12.4 mg/day in the placebo group.
Adverse events
Although low-dose MTX toxicity differs from the high doses
used in cancer chemotherapy, side effects at these low doses
may manifest in up to 60% of subjects.51 Frequently reported
side effects include abnormal liver function tests, GI symp-
toms, stomatitis, anorexia, alopecia, headaches, rashes,
pneumonia and constitutional symptoms (fatigue and reduced
concentration).52e62 Most of these adverse events reversed on
dose reduction or discontinuation of MTX therapy.
Implications for practice and research
Three meta-analyses have been performed to date on 10e12
studies, some of which are discussed in the review.51,66,67 A
Cochrane meta-analysis of the 10 trials discussed,52e60,62
demonstrated a reduction in OCS dose favouring MTX in
parallel-group trials (WMD 4.1 mg/day; 95% CI 6.8, 1.3)
and also in crossover trials (WMD 2.9 mg/day; 95% CI 5.9,
0.2).51 No improvements in FEV1 were noted and the com-
monest adverse event was hepatotoxicity. Thus, MTX may
have a small steroid-sparing effect in adult OCS-dependent
asthmatics. Similar results have been reported by the other 2
meta-analyses.66,67 The trials discussed had some flaws in
terms of the varied methodology and design, small numbers,
lack of tapering of OCS and optimisation of ICS doses prior to
randomisation, short duration of study, and variable washout
periods in the crossover studies. Although there are no pre-
dicting factors for ‘responders’, there have been subgroups
who have benefited from MTX. Also, steroid-sparing effects
may require prolonged treatment (>3 months) to appreciate
benefits, which tend to disappear on therapy discontinua-
tion. Large, adequately powered DBPC parallel-group studies
need to be conducted to elucidate the steroid-sparing role,
efficacy and safety of MTX in SRA.
Biologic therapy for severe refractory asthma
(Table 3)
Novel biologics have been developed for the treatment of
asthma in recent years and some of them might be valuable
substitutes to corticosteroid-sparing agents and immunolog-
ical modifiers. In particular, monoclonal antibodies directed
against TNF-a (infliximab, etanercept) and immunoglobulin
(Ig)E (omalizumab) have been tested in patients with chronic
severe asthma and could be useful in patients who have failed
to respond to anti-inflammatory and immunomodulatory
agents. Unlike the trials with immunological modifiers
considered above, most of the good quality studies with anti-
IgE and anti-TNF-a discussed below included only few OCS-
dependent asthmatics and only rarely the main outcome of
interest was the decrease in oral steroid dose.
Anti-IgE (omalizumab)
IgE plays a pivotal pathophysiological role in the develop-
ment of a number of allergic conditions by enhancing
allergen uptake by dendritic cells and activating mast cells
and basophils for mediator release.68
Table 3 Biologics for severe refractory asthma
Drug Evidence for
efficacy
No. of
patients
Significant
reduction in
OCS dose
Improvements in other
parameters
Common side effects for
agent
Anti-IgE e
omalizumab
(sc/iv)
 Milgrom et al.73
(DBPC)
317 Yesa Improvements in morning PEF,
QoL. Reduction in asthma
exacerbations and reliever use.
- Injection-site rashes
- Headache
- GI upsets (nausea,
abdominal pain)
 Busse et al.74
(DBPC)
525 Yes Improvements in symptom scores,
FEV1, morning PEF. Reduction in
asthma exacerbations and
reliever use.
 Soler et al.75
(DBPC)
546 Yes Improvements in symptom scores,
FEV1, morning PEF. Reduction in
asthma exacerbations and
reliever use.
 Milgrom et al.76
(DBPC)
334 Yes Reduction in asthma exacerbations
and reliever use.
 Holgate et al.77
(DBPC)
246 Yesa Reduction in reliever use.
Improvements in symptom score
and QoL.
 Humbert et al.78
(DBPC)
482 Yes Reduction in asthma exacerbations
and attendances to ER. Improvement
in QoL, morning PEF, asthma
symptom scores.
Anti-TNF-a e
etanercept
(sc)
 Berry et al.89
(CS)
10 Not assessed Improvement in FEV1, FVC, PEF,
AHR and QoL. - Injection-site reaction
- Headache
- Pharyngitis
 Morjaria et al.90
(DBPC)
39 Not assessed Improvement in asthma control.
Voluntary cessation of nebulised
reliever use.
DBPC, double-blind placebo-controlled study; ICS, inhaled corticosteroids; sc, subcutaneous; iv, intravenous; PEF, peak expiratory flow;
QoL, quality of life; FEV1, forced expiratory volume in 1 s; AHR, airway hyper-responsiveness; CS, crossover study.
a Non-significant within group improvements in the respective agent group.
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genic IgG1 that binds to free IgE at the FceRI binding site on
the C3 domain of IgE, thereby preventing its interaction with
FceRI receptors on effector cells,69,70 and has been devel-
oped for the treatment of allergic asthma. Pharmacodynamic
studies have reported the omalizumab attenuates allergen-
induced early- and late-phase responses, the acquired AHR
and inflammation, and allergen-induced skin prick tests.71,72
The evidence
An early large Phase III trial of omalizumab, administered
subcutaneously every 4 weeks at 0.016 mg/kg/IgE (IU/ml)
in an heterogeneous population including also a few OCS-
dependent asthmatics (35 out of 317, with a median
prednisone usage of 10 mg/day), demonstrated modest
improvements in asthma symptom scores and reduction in
overall corticosteroid usage (inhaled and oral), but larger
effects on reduction of asthma exacerbations.73 These
results were subsequently confirmed in at least three Phase
III clinical trials in adults, adolescents, and children with
poorly controlled allergic asthma, by demonstrating that
omalizumab improves symptom control and allows patients
to be managed with lower doses of ICS.74e76
Two other large DBPC parallel-group multicentre studies
have also included patients with OCS-dependent asthma.77,78
Holgate et al.77 recruited 246 subjects following a run-in
period for optimisation of ICS to receive sc omalizumab orplacebo for 16 weeks as add-on therapy followed by
a 12-week of ICS dose-reduction phase at 2-weekly intervals
if appropriate. There was a significantly greater reduction in
ICS and in rescue medication use with omalizumab together
with modest improvements in asthma control scores.
Although there was 35e40% reduction in exacerbation rates,
in the omalizumab group compared to placebo, this was not
statistically significant. Importantly, asthma-related QoL
reported a significant 88% improvement in the omalizumab
group compared to 39% in the placebo group.
In the study by Humbert et al.78 419 subjects with chronic
severe asthma including some22%OCS-dependent asthmatics
(with a mean OCS usage of 7.9 mg/day) were randomised to
receive either sc omalizumab or placebo for 28 weeks as add-
on therapy. There was a significant (26%) reduction in exac-
erbation rates and a 50% reduction in severe exacerbations in
the omalizumab-treated subjects compared to placebo.
Modest improvements in favour of omalizumabwere reported
for morning PEF, FEV1% predicted, total symptom and AQLQ
scores. The results presented in this study, do not allow us to
comment on potential additional effects of omalizumab in
the subgroup with OCS-dependent asthma.
Adverse events
It is worth mentioning that, in the above mentioned trials,
omalizumab-associated adverse events did not differ
significantly from placebo and most of the reported side
Immunomodulatory and biologic therapies 1507effects were minor (e.g. headaches, cough, GI symptoms,
ENT infections, urticaria and injection-site reactions).
However, a review of spontaneous post-marketing adverse
events reports identified a number of anaphylaxis and
anaphylactoid reactions (0.2% of total treated patients).79
Hence, it is now recommended that patients taking omali-
zumab should be educated regarding the signs, symptoms
and treatment of anaphylaxis and should be kept under
observation for at least 2 h after each injection.80
Implications for practice and research
Pooled analyses of omalizumab as add-on therapy have
reported significant risk reduction of exacerbations and ER
visits in moderate-to-severe asthma.81,82 Likewise, pooled
analyses of QoL outcomes have been reported to be signifi-
cantly improved with omalizumab in the steroid-stable and
reduction phases.83,84 These findings have been also
confirmed by a recent Cochrane review,85 which also indi-
cated that treatmentwith omalizumab results in a significant
reduction in ICS and rescue medication use. In view of the
large placebo effects noted and the presence of variable
baseline steroid doses as well as difference in steroid
consumption, the true effect of omalizumab remains
controversial. Moreover, it is clear that not all subjects
benefited from omalizumab treatment indicating the
importance of recognizing responders from non-responders.
Also, given that the large majority of patients with chronic
severe asthma are non-atopic with normal IgE levels, it is
likely that anti-IgE therapy with omalizumabwill be a limited
option. Sub-analyses carried out in the OCS-dependent
asthmatics (mean prednisone usage of 10.2 mg/day) rando-
mised to receive either omalizumab (nZ 50) or placebo
(nZ 45) in the study by Holgate et al.77 failed to show any
significant difference in terms of asthma exacerbations or
reduction in daily OCS dose.85 Therefore, extrapolation of
the positive effects of omalizumab in patients on step 2/3 of
the guidelines to patients with OCS-dependent asthma is not
supported by the data. Additional trials in this severe oral
steroid-dependent population are required to determine
whether they would benefit from omalizumab therapy.
Anti-TNF-a (etanercept/infliximab)
TNF-a is a multifunctional pro-inflammatory cytokine (TH1)
whose effects are regulated both by local concentrations
and cell surface receptor dynamics. TNF-a has been impli-
cated in the initiation and perpetuation of the asthmatic
inflammatory process, epithelial damage and remodelling,
AHR and mucin hypersecretion86 and it has been reported
to be elevated in subjects with severe asthma.87 Beneficial
antagonism of TNF-a has been shown in a range of chronic
inflammatory disorders including rheumatoid arthritis,
juvenile arthritis, ankylosing spondylitis, Crohn’s disease
and psoriasis.88
The evidence
Efficacy of TNF-a antagonism, using the soluble TNF-
a receptor (TNFR) fusion protein, etanercept, has been also
reported in 2 small studies of chronic severe asthmatics.87,89
Objective improvements of lung function (FEV1, FVC and
PEF) as well as AHR with methacholine were reported.Significant subjective improvements of asthma control87 and
asthma-related QoL89 were also noted. All but one subject
voluntarily withdrew from using regular nebulised broncho-
dilators, but the beneficial effects last only 2e4 weeks after
termination of treatment, reverting back to pre-treatment
levels.87 In another more recent larger DBPC study by Mor-
jaria et al.90 the use of etanercept failed to show any
significant subjective as well as objective improvements in
patients with SRA, with the exception of ACQ scores.
Although steroid dose reduction was not included as a study
endpoint, it is however worth mentioning that 4 patients
randomised in the etanercept arm of the study completely
withdrew the use of nebulised salbutamol.
Conversely, a DBPC study in mild-to-moderate asthmatics
using the chimeric mouse/human monoclonal anti-TNF-
a antibody, infliximab, failed to demonstrate any definite
improvements as reported in the more severe studies.91Adverse events
Safety data on TNF-a antagonists has mostly been gathered
from clinical studies of rheumatoid arthritis subjects where
they have proven to be safe and well tolerated.92,93
However, some adverse events have been reported and the
long-term safety of these biological agents have not been
thoroughly evaluated. Adverse events seen include increase
risk of malignancy, opportunistic infections and reac-
tivation of tuberculosis, demyelination and worsening
cardiac failure.86 A recent meta-analysis of the risk of
serious infections and development of malignancy has
recently been reported.94 In the conducted asthma trials
to-date TNF-a antagonism has shown no major adverse
events of note.86,87,89,91 The minor side effects seen noted
include injection-site reactions, skin rashes, respiratory
tract infections and headaches.
Implications for practice and research
Overall, the role of anti-TNF treatment in SRA appears to be
rather disappointing. However, additional considerations
may explain the essentially negative findings of the above
mentioned studies. First, the total symptoms score showed
a large improvement over placebo, potentially offsetting
any benefit observed within anti-TNF treatment; why
patients with chronic severe asthma on placebo manifested
such substantial improvements remains to be investigated.
Second, the degree of disease severity in some of the trials
discussed above may not be adequate to show a significant
response; this is particularly pertinent for the study in mild-
to-moderate asthmatics91 where, given the larger role of
TNF-a on airway inflammation in the more severe end of
the disease spectrum, the observed lack of efficacy in mild-
to-moderate asthma patients is not unexpected. Third, it is
also possible that the dose was too low and the duration of
the trials too short to detect significant changes. Last, the
small sample size of these trials did not have enough power
to detect changes. Nonetheless, some patients clearly
benefited from anti-TNF treatment indicating, once again,
the importance of recognizing responders from non-
responders. Large clinical trials with etanercept and
a variety of anti-TNF-a monoclonal antibodies are now in
progress to evaluate the efficacy, safety and possibly
steroid-sparing benefits of this subclass of biologics.
Practice points and research implications
In spite of encouraging developments in asthma management, there is a small subset of patients whose asthma
continues to be seriously symptomatic despite aggressive treatment with high-dose ICS and b2-agonists. In these
patients, reasonable symptom control is often achieved by regular systemic corticosteroids at the cost of significant
adverse effects. Steroid tapering and reduction of their adverse effects may be achieved in SRA through add-on
therapies with anti-inflammatory drugs, immunologic modifiers and biologic therapies.
These agents are infrequently used in patients with SRA. One of the reasons why these agents may have limited
acceptance by respiratory physicians is because of concern in term of lack of efficacy and of unacceptable side effects.
These safety concerns may be unfounded and need to be weighed against the significant adverse effects of long-term
systemic corticosterioids. There is a large and growing experience of using immunologic modifiers to treat chronic
inflammatory rheumatic diseases. This experience shows us that immunologic modifiers are effective for some but not
for all patients, and that significant benefits may take months to occur. Moreover, most immunologic modifiers at low
dose appear to be safe for long-term use, providing careful monitoring of patients’ symptoms and laboratory tests is
arranged.
Unfortunately, the large majority of the trials presented in this review article fail to support their role in OCS-
dependent asthma because of major drawbacks in methodology, small sample size, heterogeneous patient pop-
ulations, unsatisfactory follow-up period, lack of adequate run-in for stabilization of patients’ steroid requirements,
poorly defined response criteria for steroid tapering, short treatment duration and under-dosing are probably
important causes for the inconclusive results reported in SRA. Apart from these obvious methodological considerations,
the large placebo effect observed in some trials and the considerable heterogeneity in the drug response in individual
patients requires additional care when designing clinical trials in patients with SRA.
In future, more efforts should be devoted towards determining the best use of anti-inflammatory, immunologic
modifiers and biologic therapies in SRA and for the detection of the key characteristics of those who are going to
respond to these agents. In an ideal world, SRA subjects might be considered for inclusion in a range of collaborative
trials of add-on therapies that better control their asthma. The development of novel and powerful therapies that
reduce the need for systemic corticosteroids in patients with severe refractory asthma should be a main priority for the
academic world and the pharmaceutical industry.
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